Deborah Minor

Innovation in pharmaceutical development rarely happens in isolation. As scientific complexity increases and development timelines become more demanding, collaboration across biotech companies, academic institutions, and large pharmaceutical organizations has become one of the most effective ways to advance programs from discovery to commercialization. Strategic alliances are helping companies move faster, reduce risk, and access specialized expertise that may not exist internally. From...

In drug development, the difference between a program that advances on schedule and one that stalls rarely comes down to the science. More often, it comes down to whether the right expertise was available at the right moment. For emerging biotech and biopharma companies, that expertise is frequently absent precisely when it is needed most: at the inflection points where CMC strategy, regulatory documentation, and manufacturing execution demand senior-level leadership. Drug Discovery Alliances...

As drug development programs advance, the challenges they face evolve, but the cost of misalignment remains constant. Gaps in CMC can quietly derail timelines, strain resources, and introduce unnecessary risk at critical inflection points. Recognizing this reality, Drug Discovery Alliances (DDA) is expanding its CMC consulting network to provide deeper, more flexible support across every phase of R&D, from discovery through commercial launch. CMC Expertise When and Where It’s Needed Most CMC...